RxDoctor Payments DataLook up a doctor →

Richard Miller, MD

Psychiatry · Cranston, RINPI 1114122595

Payments from drug & device makers

$864,224in general payments, 2019–2025

Across 1,168 payments — averaging $739.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$310K
  • Alkermes, Inc.$297K
  • Johnson & Johnson$205K
  • Otsuka America Pharmaceutical, Inc.$39K
  • E.r. Squibb & Sons, L.L.C.$12K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$275
  • plus $268 from 4 others

What the payments were for

  • Consulting fees$65,7978%
  • Speaking & faculty fees$707,57782%
  • Travel & lodging$63,7877%
  • Food & beverage$26,6193%
  • Education$4440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$864,224 in reported general payments places this provider in the 95th percentile of 209 psychiatry providers in Rhode Island.

See all psychiatry providers in Rhode Island

Medicare billing

Part B allowed, 2024
$20,388
Medicare patients
52
Services billed
342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate120$388,191
UzedyRisperidone48$179,852
Austedo XrDeutetrabenazine19$140,217
AristadaAripiprazole Lauroxil40$137,609
LybalviOlanzapine/Samidorphan Malate49$72,947
Clozapine346$33,223
RexultiBrexpiprazole27$24,542
Chlorpromazine Hcl47$8,354
Divalproex Sodium98$3,933
Quetiapine Fumarate161$3,518
Glycopyrrolate57$3,038
Duloxetine Hcl140$2,723
Haloperidol36$2,675
Benztropine Mesylate192$2,632
Bupropion XlBupropion Hcl73$2,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$205,002$388,191120 claims
Teva Pharmaceuticals USA, Inc.Uzedy, Austedo Xr$310,054$320,06967 claims
Alkermes, Inc.Aristada, Lybalvi$297,165$210,55689 claims
Otsuka America Pharmaceutical, Inc.Rexulti$39,164$24,54227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 209 psychiatry providers in Rhode Island.

Other psychiatry in Cranston

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →